Can Adjuvant Chemoradiotherapy Replace Extended Lymph Node Dissection in Gastric Cancer?

  • Edwin P. M. Jansen
  • Henk Boot
  • Cornelis J. H. van de Velde
  • Johanna van Sandick
  • Annemieke Cats
  • Marcel Verheij
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 196)


Surgical resection remains the essential part in the curative treatment of gastric cancer. However, with surgery only, long-term survival is poor (5-year survival <25 % in Europe). Randomized studies, which compared limited (D1) lymph node dissection with more extended (D2) resections in the Western world, failed to show a survival benefit for more extensive surgery. A substantial increase in survival was found with perioperative chemotherapy in the MAGIC study. In addition, the SWOG/Intergroup 0116 study showed that postoperative chemoradiotherapy (CRT) prolonged 5-year overall survival compared to surgery only. However, it has been argued that surgical undertreatment undermined survival in this trial. In a randomized Korean study, patients with advanced stage gastric cancer who received postoperative CRT had better outcome after a D2 dissection. At our institute phase I-II studies with adjuvant cisplatin and capecitabine-based CRT have been performed in over 120 patients with resected gastric cancer. Retrospective comparison of patients treated in these studies with those that had surgery only in the D1D2 study, demonstrated that postoperative CRT was associated with better outcome, especially after D1 or a R1 resection. For daily practice, it remains unclear whether patients after optimal (D2) gastric surgery will benefit from postoperative CRT. This is currently being tested in prospective randomized phase III trials (CRITICS; TOPGEAR).


Gastric Cancer Intensity Modulate Radio Therapy Extend Lymph Node Dissection Locoregional Recurrence Rate Maruyama Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D (1991) Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 68:1501–1506PubMedCrossRefGoogle Scholar
  2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar
  3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321PubMedCrossRefGoogle Scholar
  4. Bischof D, Swallow C, Stotland P, Hagen J, Klein L (2012) Incorporation of laparoscopic D2 dissection into the management of gastric adenocarcinoma (GCa) in a community-based setting. J Clin Oncol 30:(suppl 4; abstract 117)Google Scholar
  5. Cascinu S, Giordani P, Catalano V, Agostinelli R, Catalano G (1999) Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical management. Jpn J Clin Oncol 29:291–293PubMedCrossRefGoogle Scholar
  6. Coburn NG, Guller U, Baxter NN, Kiss A, Ringash J, Swallow CJ, Law CH (2008) Adjuvant therapy for resected gastric cancer-rapid, yet incomplete adoption following results of intergroup 0116 trial. Int J Radiat Oncol Biol Phys 70:1073–1080PubMedCrossRefGoogle Scholar
  7. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial P (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20Google Scholar
  8. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Montgomery E, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD (2005) Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 9:718–725PubMedCrossRefGoogle Scholar
  9. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW (2010) Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 46:1101–1110PubMedCrossRefGoogle Scholar
  10. de Gara CJ, Hanson J, Hamilton S (2003) A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival. Am J Surg 186:23–27PubMedCrossRefGoogle Scholar
  11. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M (2010) Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 28:2430–2436PubMedCrossRefGoogle Scholar
  12. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35:1059–1064PubMedCrossRefGoogle Scholar
  13. Fiorica F, Cartei F, Enea M, Licata A, Cabibbo G, Carau B, Liboni A, Ursino S, Camma C (2007) The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev 33:729–740PubMedCrossRefGoogle Scholar
  14. Gianni L, Panzini I, Tassinari D, Mianulli AM, Desiderio F, Ravaioli A (2001) Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 12:1178–1180PubMedGoogle Scholar
  15. GITSG (1982) A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal tumor study group. Cancer 49:1771–1777CrossRefGoogle Scholar
  16. GITSG (1990) The concept of locally advanced gastric cancer. Effect of treatment on outcome. Gastrointest tumor study group. Cancer 66:2324–2330CrossRefGoogle Scholar
  17. Hallissey MT, Jewkes AJ, Dunn JA, Ward L, Fielding JW (1993) Resection-line involvement in gastric cancer: a continuing problem. Br J Surg 80:1418–1420PubMedCrossRefGoogle Scholar
  18. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ (2009) Gastric cancer. Lancet 374:477–490PubMedCrossRefGoogle Scholar
  19. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH (2004) Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30:643–649PubMedCrossRefGoogle Scholar
  20. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, van de Velde CJ (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447PubMedGoogle Scholar
  21. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, Wang L, Wang CH, Chen HY, Li YP (2002) Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol 8:1023–1028PubMedGoogle Scholar
  22. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T (2002) Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 9:278–286PubMedCrossRefGoogle Scholar
  23. Jahne J, Piso P, Meyer HJ (2001) 1114 total gastrectomies in the surgical treatment of primary gastric adenocarcinoma–a 30-year single institution experience. Hepatogastroenterology 48:1222–1226PubMedGoogle Scholar
  24. Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M (2007a) Postoperative chemoradiotherapy in gastric cancer—a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. Br J Cancer 97:712–716PubMedCrossRefGoogle Scholar
  25. Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A (2010) Postoperative chemoradiotherapy in gastric cancer–a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Ann Oncol 21:530–534PubMedCrossRefGoogle Scholar
  26. Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A (2007b) A Phase I-II Study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 69:1424–1428PubMedCrossRefGoogle Scholar
  27. Jansen EP, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Valdes Olmos R, Bartelink H, Verheij M (2007c) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67:781–785PubMedCrossRefGoogle Scholar
  28. Jensen LS, Nielsen H, Mortensen PB, Pilegaard HK, Johnsen SP (2010) Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol 36 Suppl 1:S50–S54PubMedCrossRefGoogle Scholar
  29. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21:3647–3650PubMedCrossRefGoogle Scholar
  30. Kim S, Lim do H, Lee J, Kang WK, Macdonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279–1285PubMedCrossRefGoogle Scholar
  31. Kim SH, Karpeh MS, Klimstra DS, Leung D, Brennan MF (1999) Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg 3:24–33PubMedCrossRefGoogle Scholar
  32. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an eastern cooperative oncology group study. J Clin Oncol 3:373–378PubMedGoogle Scholar
  33. Kozak KR, Moody JS (2008) The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 72:517–521Google Scholar
  34. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273PubMedCrossRefGoogle Scholar
  35. Lepage C, Sant M, Verdecchia A, Forman D, Esteve J, Faivre J (2010) Operative mortality after gastric cancer resection and long-term survival differences across Europe. Br J Surg 97:235–239PubMedCrossRefGoogle Scholar
  36. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRefGoogle Scholar
  37. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo studio dei carcinomi dell’apparato digerente). Ann Oncol 11:837–843PubMedCrossRefGoogle Scholar
  38. McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J (2004) Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 4:CD001964Google Scholar
  39. Moertel CG, Childs DS, O’Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ (1984) Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 2:1249–1254PubMedGoogle Scholar
  40. Morgagni P, Garcea D, Marrelli D, de Manzoni G, Natalini G, Kurihara H, Marchet A, Saragoni L, Scarpi E, Pedrazzani C, Di Leo A, De Santis F, Panizzo V, Nitti D, Roviello F (2008) Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients. World J Surg 32:2661–2667PubMedCrossRefGoogle Scholar
  41. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6:159–167PubMedCrossRefGoogle Scholar
  42. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303:1729–1737PubMedCrossRefGoogle Scholar
  43. Ringash J, Perkins G, Brierley J, Lockwood G, Islam M, Catton P, Cummings B, Kim J, Wong R, Dawson L (2005) IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys 63:732–738PubMedCrossRefGoogle Scholar
  44. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  45. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45:931–991PubMedCrossRefGoogle Scholar
  46. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393PubMedCrossRefGoogle Scholar
  47. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359:453–462PubMedCrossRefGoogle Scholar
  48. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Cutsem EV, Siewert JR, Schlag PM (2010) neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: european organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol 28:5210–5218PubMedCrossRefGoogle Scholar
  49. Shiu MH, Moore E, Sanders M, Huvos A, Freedman B, Goodbold J, Chaiyaphruk S, Wesdorp R, Brennan MF (1987) Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. Arch Surg 122:1347–1351PubMedCrossRefGoogle Scholar
  50. Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg 228:449–461PubMedCrossRefGoogle Scholar
  51. Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ (1996) Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer 32A:433–437PubMedCrossRefGoogle Scholar
  52. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449PubMedCrossRefGoogle Scholar
  53. Sun P, Xiang JB, Chen ZY (2009a) Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 96:26–33PubMedCrossRefGoogle Scholar
  54. Sun Z, Li DM, Wang ZN, Huang BJ, Xu Y, Li K, Xu HM (2009b) Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol 16:3028–3037PubMedCrossRefGoogle Scholar
  55. Valentini V, Cellini F, Minsky BD, Mattiucci GC, Balducci M, D’Agostino G, D’Angelo E, Dinapoli N, Nicolotti N, Valentini C, La Torre G (2009) Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 92:176–183PubMedCrossRefGoogle Scholar
  56. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Jr., Winchester D, Osteen R (1993) Cancer of the stomach. A patient care study by the American college of surgeons. Ann Surg 218:583–592PubMedCrossRefGoogle Scholar
  57. Wang SY, Yeh CN, Lee HL, Liu YY, Chao TC, Hwang TL, Jan YY, Chen MF (2009) Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 16:2738–2743PubMedCrossRefGoogle Scholar
  58. Wieland P, Dobler B, Mai S, Hermann B, Tiefenbacher U, Steil V, Wenz F, Lohr F (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 59:1236–1244PubMedCrossRefGoogle Scholar
  59. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J (2006) Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7:309–315PubMedCrossRefGoogle Scholar
  60. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721PubMedCrossRefGoogle Scholar
  61. Yu CC, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, Hallisey MT (1995) Pathological prognostic factors in the second British stomach cancer group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer 71:1106–1110PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Edwin P. M. Jansen
    • 1
  • Henk Boot
    • 2
  • Cornelis J. H. van de Velde
    • 4
  • Johanna van Sandick
    • 3
  • Annemieke Cats
    • 2
  • Marcel Verheij
    • 1
  1. 1.Department of RadiotherapyAntoni van Leeuwenhoek Hospital, The Netherlands Cancer InstituteAmsterdamThe Netherlands
  2. 2.Department of GastroenterologyAntoni van Leeuwenhoek Hospital, The Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of SurgeryAntoni van Leeuwenhoek Hospital, The Netherlands Cancer InstituteAmsterdamThe Netherlands
  4. 4.Department of SurgeryLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations